https://doi.org/10.4081/hmr.v2i5.761

Lestaurtinib as a FLT3 inhibitor

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 149
PDF: 165
Untitled (): 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

AK Burnett
support@pagepress.org
Overexpression of the FLT-3 receptor is common in Acute Myeloid Leukaemia (AML) and mutations represent one of the commonest mutations which occur in approximately 30% of adult cases, although less frequent in older patients. The most frequently detected mutation is an Internal Tandem Duplication (ITD) in the juxtamembrane position of the receptor (24%), and a point mutation in the activation loop usually at positive 385 (7%). The mutations are in frame and constitutively activate via STAT5. Mutations are unevenly distributed in FAB and cytogenetic groups. They have highest frequency in Acute Promyelocytic Leukaemia (35-40%), and are associated with a normal karyotypic or trisomy 8. They are less frequent in poor risk karyotypes or in core binding leukaemias. The association with normal karytyope has the additional interest of being associated with mutations of the nucleophosmin 1 mutation in approximately two-thirds of cases. Whether these mutations are themselves leukaemogenic is thought to be unlikely.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Burnett, A. (2009). Lestaurtinib as a FLT3 inhibitor. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.761
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).